Literature DB >> 16477914

National survey of radiotherapy fractionation practice in 2003.

M V Williams1, N D James, E T Summers, A Barrett, D V Ash.   

Abstract

AIMS: To document UK practice in radiotherapy fractionation.
METHODS: All radiotherapy centres in the UK participated in a 1-week audit from 29 September 2003. Fractionation data were collected for all patients starting external beam radiotherapy. This included 2498 patients who were prescribed 32 547 fractions.
RESULTS: For the radical treatment of non-skin malignancy (n = 708), the prescribed dose ranged from a single fraction of 8 Gy for total-body irradiation to 75 Gy in 43 fractions for prostate cancer. Postoperative treatment for breast cancer was dominated by three regimens: 40 Gy in 15 fractions; 45 Gy in 20 fractions; and 50 Gy in 25 fractions. Palliative treatment was given in a single fraction to 393 patients (36%) with doses of up to 15 Gy. Three hundred and ninety patients (36%) received four to seven fractions delivering 20-25 Gy. Only 89 patients (8%) received more than 10 fractions with palliative intent but used 29% of such fractions. In the treatment of bone metastases, the most common prescriptions were 8-10 Gy in a single fraction and 20 Gy in five fractions.
CONCLUSION: UK radiotherapy practice has become more uniform and moved closer to practice in North America and Europe over the past 15 years. For radical radiotherapy, 54% of prescriptions were for a fraction size of 1.8-2.0 Gy but the distribution was bi-modal and 20% of patients were prescribed fraction sizes of 2.7-3.0 Gy. Evidence-based practice now supports hypo-fractionated palliative treatment favouring single fractions for bone metastases and one or two fractions for many patients with advanced lung cancer. Two fractions are advised for some patients with brain metastasis. If these guidelines had been applied uniformly, then the number of treatments prescribed for palliation could have fallen by 36% from 5197 to 3313. This would have represented a 6% reduction in the overall radiotherapy workload. Not all patients are suitable for such hypo-fractionated treatments, but this is an area in which resource use can be improved. In the postoperative management of breast cancer, a change in practice to use 15 fractions uniformly would reduce overall radiotherapy workload by 4%. By contrast, a change to 25 fractions would increase overall workload by 7%.

Entities:  

Mesh:

Year:  2006        PMID: 16477914     DOI: 10.1016/j.clon.2005.10.002

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  13 in total

1.  Ten-year results of accelerated hypofractionated adjuvant whole-breast radiation with concomitant boost to the lumpectomy cavity after conserving surgery for early breast cancer.

Authors:  Domenico Cante; Edoardo Petrucci; Piera Sciacero; Cristina Piva; Silvia Ferrario; Silvia Bagnera; Sebastiano Patania; Guido Mondini; Massimo Pasquino; Valeria Casanova Borca; Giorgio Vellani; Maria Rosa La Porta; Pierfrancesco Franco
Journal:  Med Oncol       Date:  2017-08-03       Impact factor: 3.064

Review 2.  Therapeutic potential of natural plant products and their metabolites in preventing radiation enteropathy resulting from abdominal or pelvic irradiation.

Authors:  Rupak Pathak; Sumit K Shah; Martin Hauer-Jensen
Journal:  Int J Radiat Biol       Date:  2019-01-08       Impact factor: 2.694

Review 3.  Review of patterns of practice and patients' preferences in the treatment of bone metastases with palliative radiotherapy.

Authors:  Nicole M E Bradley; Janice Husted; Michael Sai Lai Sey; Amna F Husain; Emily Sinclair; Kristin Harris; Edward Chow
Journal:  Support Care Cancer       Date:  2006-11-09       Impact factor: 3.359

4.  Definitive hypofractionated radiotherapy for early glottic carcinoma: experience of 55Gy in 20 fractions.

Authors:  Ekin Ermiş; Mark Teo; Karen E Dyker; Chris Fosker; Mehmet Sen; Robin Jd Prestwich
Journal:  Radiat Oncol       Date:  2015-09-23       Impact factor: 3.481

Review 5.  International patterns of practice in radiotherapy for bone metastases: A review of the literature.

Authors:  Rachel McDonald; Edward Chow; Henry Lam; Leigha Rowbottom; Hany Soliman
Journal:  J Bone Oncol       Date:  2014-11-07       Impact factor: 4.072

6.  Post-Surgery Glioma Growth Modeling from Magnetic Resonance Images for Patients with Treatment.

Authors:  Ahmed Elazab; Hongmin Bai; Yousry M Abdulazeem; Talaat Abdelhamid; Sijie Zhou; Kelvin K L Wong; Qingmao Hu
Journal:  Sci Rep       Date:  2017-04-27       Impact factor: 4.379

Review 7.  Practice-changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie?

Authors:  Mareike K Thompson; Philip Poortmans; Anthony J Chalmers; Corinne Faivre-Finn; Emma Hall; Robert A Huddart; Yolande Lievens; David Sebag-Montefiore; Charlotte E Coles
Journal:  Br J Cancer       Date:  2018-07-31       Impact factor: 7.640

8.  The emerging role of IG-IMRT for palliative radiotherapy: a single-institution experience.

Authors:  R Samant; L Gerig; L Montgomery; R Macrae; G Fox; B Nyiri; K Carty; M Macpherson
Journal:  Curr Oncol       Date:  2009-05       Impact factor: 3.677

9.  The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.

Authors:  S M Bentzen; R K Agrawal; E G A Aird; J M Barrett; P J Barrett-Lee; S M Bentzen; J M Bliss; J Brown; J A Dewar; H J Dobbs; J S Haviland; P J Hoskin; P Hopwood; P A Lawton; B J Magee; J Mills; D A L Morgan; J R Owen; S Simmons; G Sumo; M A Sydenham; K Venables; J R Yarnold
Journal:  Lancet       Date:  2008-03-19       Impact factor: 79.321

10.  Did the pattern of practice in the prescription of palliative radiotherapy for the treatment of uncomplicated bone metastases change between 1999 and 2005 at the rapid response radiotherapy program?

Authors:  N M E Bradley; J Husted; M S L Sey; E Sinclair; K K Li; A F Husain; C Danjoux; E A Barnes; M N Tsao; L Barbera; K Harris; H Chiu; M Doyle; E Chow
Journal:  Clin Oncol (R Coll Radiol)       Date:  2008-02-13       Impact factor: 4.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.